Acuta Capital Partners, LLC Kal Vista Pharmaceuticals, Inc. Transaction History

Acuta Capital Partners, LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2020 May 15, 2020	SELL	$5.8 - $18.56 $623,500 - $2 Million	-107,500 Closed	0 $0
Q4 2019 Feb 14, 2020	BUY	$10.31 - $17.81 $850,575 - $1.47 Million	82,500 Added 330.0%	107,500 $1.92 Million
Q3 2019 Nov 14, 2019	SELL	$11.6 - $21.67 $2.18 Million - $4.07 Million	-188,000 Reduced 88.26%	25,000 $290,000
Q2 2019 Aug 14, 2019	BUY	$18.44 - $30.89 $138,300 - $231,675	7,500 Added 3.65%	213,000 $4.72 Million
Q1 2019 May 14, 2019	BUY	$16.51 - $31.1 $536,575 - $1.01 Million	32,500 Added 18.79%	205,500 $5.88 Million
Q4 2018 Feb 14, 2019	BUY	$16.21 - $24.06 $715,768 - $1.06 Million	44,156 Added 34.27%	173,000 $3.42 Million
Q3 2018 Nov 07, 2018	BUY	$8.0 - $22.11 $1.03 Million - $2.85 Million	128,844 New	128,844 $2.85 Million

126

47.9M

551K

110K

Ticker KALV
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 24,602,000
Market Cap $214M
Description
KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors for diseases with unmet needs. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral p...

Get notified when there are updates to the investment portfolio of Acuta Capital Partners, LLC, based on Form 13F filings with the SEC.

Stay updated on Acuta Capital Partners, LLC with notifications on news.